Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 16/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14015669 | 0.82 | KDM4E (0.42) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15491596 | 0.78 | KDM4E (0.46) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL1775809 | 0.78 | KDM4E (0.46) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15484896 | 0.75 | KDM4E (0.44) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15492970 | 0.73 | KDM4E (0.45) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL1119932 | 0.71 | KDM4E (0.46) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15491625 | 0.71 | KDM4E (0.46) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15491626 | 0.71 | KDM4E (0.46) | KDM4ERECQLCCR1TDP1NLRP3 | |
| SCHEMBL15779544 | 0.69 | KDM4E (0.44) | KDM4ERECQLCCR1TDP1 | |
| SCHEMBL4232846 | 0.69 | KDM4E (0.49) | KDM4ERECQLCCR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342781-B2 | Diazole amides | CHEMOCENTRYX, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180071257-A1 | DIAZOLE AMIDES | CHEMOCENTRYX, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071257-A1 | DIAZOLE AMIDES | CCR1, CCRL2, CCR4 | KDM4E 3623/4885RECQL 2677/4885CCR1 1/4885 |
| US-10342781-B2 | Diazole amides | CCR1, CCRL2, CCR4 | KDM4E 3623/4885RECQL 2677/4885CCR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.